These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34731493)

  • 21. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
    Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
    Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis.
    Marletta D; Murgia G; Cattaneo A; Carrera C; Marzano A
    J Drugs Dermatol; 2022 Aug; 21(8):864-866. PubMed ID: 35946964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).
    Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K
    BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study.
    Gargiulo L; Ibba L; Cortese A; Toso F; Vignoli CA; Fiorillo G; Piscazzi F; Valenti M; Costanzo A; Narcisi A
    J Drugs Dermatol; 2024 Aug; 23(8):632-639. PubMed ID: 39093650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
    Teeple A; Fitzgerald T
    J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks.
    Galluzzo M; Marcelli L; Vellucci L; Paganini C; Maffei V; Tofani L; Belcastro A; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2023 Apr; 23(4):371-381. PubMed ID: 36971507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry.
    Hugo J; Kojanova M; Turkova B; Gkalpakiotis S;
    Dermatol Ther (Heidelb); 2023 Mar; 13(3):787-801. PubMed ID: 36723775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience.
    Megna M; Fabbrocini G; Cinelli E; Camela E; Ruggiero A
    J Dermatolog Treat; 2022 Mar; 33(2):1074-1078. PubMed ID: 32705907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 34. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.
    Ruggiero A; Fabbrocini G; Cinelli E; Megna M
    Dermatol Ther; 2022 Jan; 35(1):e15214. PubMed ID: 34800070
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.
    Reich K; Gordon KB; Strober B; Langley RG; Miller M; Yang YW; Shen YK; You Y; Zhu Y; Foley P; Blauvelt A
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2393-2400. PubMed ID: 35920762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.
    Schäkel K; Reich K; Asadullah K; Pinter A; Jullien D; Weisenseel P; Paul C; Gomez M; Wegner S; Personke Y; Kreimendahl F; Chen Y; Angsana J; Leung MWL; Eyerich K
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2016-2027. PubMed ID: 37262309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
    Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
    J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
    Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
    J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.